Leptin Signaling in Lean and Obese Humans (Leptin signali)

This study has been withdrawn prior to enrollment.
(funding expired)
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT01297426
First received: February 14, 2011
Last updated: December 23, 2015
Last verified: December 2015

February 14, 2011
December 23, 2015
April 2011
June 2015   (final data collection date for primary outcome measure)
Westerns / activation of signaling pathways (uo to two hours after treatment) [ Time Frame: 04/01/2016 ] [ Designated as safety issue: No ]
Westerns / activation of signaling pathways [ Time Frame: 04/01/2016 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01297426 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Leptin Signaling in Lean and Obese Humans
Leptin Signaling in Humans
Obesity does not respond to high circulating levels of the hormone leptin. This study is aiming at finding out why this happens and open new avenues for treatment of obesity.
Ex vivo and in vitro identification and study of leptin signaling pathways in commercially available cell lines serum/ plasma samples and discarded tissues from humans.
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
diabetic or nondiabetic lean and obese subjects
Obesity
Not Provided
Group 1
Lean and obese, diabetic and non diabetics
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • men and women
  • ages 18 to 65
  • BMI ranges between 20 and 45 kg/m2

Exclusion Criteria:

  • subjects requiring special diets
  • history of illness other than obesity of diabetes
  • taking medications known to influence glucose metabolism
  • subjects with history of anaphylactic reaction or hypersensitivity to e. coli derived proteins or anesthetic agents
  • women who are breastfeeding, pregnant or wanting to become pregnant
  • subjects with bleeding dyscrasia or poor wound healing
Both
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01297426
ENDA-013-10F
No
Not Provided
Not Provided
VA Office of Research and Development
VA Office of Research and Development
Not Provided
Principal Investigator: Christos Mantzoros, MD DSc VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
VA Office of Research and Development
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP